Promising Dual-Therapy approach targets recurrent prostate cancer in early trial
NCT ID NCT06105918
First seen Dec 15, 2025 · Last updated May 16, 2026 · Updated 22 times
Summary
This early-phase trial tests the safety and best dose of a radioactive drug (177Lu-rhPSMA-10.1) given after targeted radiation therapy in men whose prostate cancer has returned after prostate removal surgery. The study involves 6 participants and uses a special scan (PSMA PET) to guide treatment directly to cancer cells. The goal is to see if this combination can kill more tumor cells while limiting side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.